Reqorsa® (quaratusugene ozeplasmid) + Tecentriq® (atezolizumab)

About Genprex

Genprex is focused on developing life-changing gene therapies for cancer patients, leveraging its unique platform to deliver tumor suppressor genes directly to cancer cells. The company's core technology, the ONCOPREX® Nanoparticle Delivery System, is designed to overcome the limitations of viral vectors and enable systemic administration. Its lead program, Reqorsa®, which delivers the TUSC2 gene, is in multiple clinical trials for lung cancer, positioning the company at the forefront of non-viral gene therapy in oncology. Genprex's strategy involves advancing its pipeline through clinical development and seeking strategic partnerships to maximize the potential of its platform.

Therapeutic Areas

Other Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Drugs